BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zheng ZY, Chu MY, Lin W, Zheng YQ, Xu XE, Chen Y, Liao LD, Wu ZY, Wang SH, Li EM, Xu LY. Blocking STAT3 signaling augments MEK/ERK inhibitor efficacy in esophageal squamous cell carcinoma. Cell Death Dis 2022;13:496. [PMID: 35614034 DOI: 10.1038/s41419-022-04941-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Xu M, Fang K, Sun M, Leng Z, Chu Y, Zhao Z, Li Z, Zhang Y, Xu A, Zhang Z, Zhang L, Chen T. Targeting IGF1R signaling enhances the sensitivity of cisplatin by inhibiting proline and arginine metabolism in oesophageal squamous cell carcinoma under hypoxia condition.. [DOI: 10.21203/rs.3.rs-2269651/v1] [Reference Citation Analysis]
2 Sha Y, Hong H, Cai W, Sun T. Single-Cell Transcriptomics of Endothelial Cells in Upper and Lower Human Esophageal Squamous Cell Carcinoma. Curr Oncol 2022;29:7680-94. [PMID: 36290884 DOI: 10.3390/curroncol29100607] [Reference Citation Analysis]
3 Chang X, Wang J, Bian J, Liu Z, Guo M, Li Z, Wu Y, Zhai X, Zuo D. 1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-(2-(dimethylamino)ethyl)imidazolidin-2-one (ZX-42) inhibits cell proliferation and induces apoptosis via inhibiting ALK and its downstream pathways in Karpas299 cells. Toxicol Appl Pharmacol 2022;450:116156. [PMID: 35803438 DOI: 10.1016/j.taap.2022.116156] [Reference Citation Analysis]